Skip to main content Skip to search Skip to main navigation

German Bundestag Passes Cannabis Law

On 23 February, the German Bundestag approved the government's bill on the "controlled use of cannabis". The law allows adults to possess up to 50 grams of cannabis in private and up to 25 grams in public.

It allows the private cultivation of up to three plants and the distribution by cultivation associations under strict regulations. A maximum of 25 grams per day or 50 grams per month can be given to members. The distribution of cannabis to adolescents between the ages of 18 and 21 is permitted up to 30 grams per month with a limit of ten per cent THC content. Cannabis for consumption may only be distributed as hashish or marijuana of controlled quality and in pure form; medical cannabis remains subject to prescription.

Advertising for cannabis and cultivation associations will be banned, and a prevention campaign is planned. The reform will enter into force on 1 April 2024, while the regulations on cultivation associations will enter into force on 1 July 2024.

The German Bundesrat (Federal Council) will hold a final debate on the Cannabis Act on 22 March. It does not need to be approved there. However, the Federal Council could appeal to the Conciliation Committee and thus delay its implementation.


Source:

German Bundestag: Dokumente 2024


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next